Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
2003-06-30
2008-12-16
Sirmons, Kevin C (Department: 3767)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
Reexamination Certificate
active
07465298
ABSTRACT:
Methods, systems, and apparatus for delivering drugs and other substances to extraluminal tissue surrounding a body lumen are described. Catheters are used to inject the drug or other substance intraluminally into tissue surrounding a stent or other luminal scaffold. The drug or other substance is injected in an amount sufficient to cause diffusion back through the tissue to the stent. An absorptive structure, reservoir, or the like, on the stent then absorbs excess drug as it passes from the luminal tissue. In this way, the stent is first loaded with drug. After time, as the stent becomes fully loaded and the tissue becomes depleted, drug will be begin to flow back from the stent into the surrounding luminal tissue.
REFERENCES:
patent: 5112305 (1992-05-01), Barath et al.
patent: 5196024 (1993-03-01), Barath
patent: 5354279 (1994-10-01), Hofling
patent: 5538504 (1996-07-01), Linden et al.
patent: 5645564 (1997-07-01), Northrup et al.
patent: 5681281 (1997-10-01), Vigil et al.
patent: 5693029 (1997-12-01), Leonhardt
patent: 5722989 (1998-03-01), Fitch et al.
patent: 6059815 (2000-05-01), Lee et al.
patent: 6102933 (2000-08-01), Lee et al.
patent: 6283947 (2001-09-01), Mirzaee
patent: 6605114 (2003-08-01), Yan et al.
patent: 6776792 (2004-08-01), Yan et al.
patent: 2002/0002349 (2002-01-01), Flaherty et al.
patent: 2002/0077592 (2002-06-01), Barry
Braun-Dullaeus et al., “Cell cycle progression: new therapeutic target for vascular proliferative disease.”Circulation. 1998; 98(1):82-9.
Chan et al., “Update on Pharmacology for Restenosis,”Current Interventional Cardiology Reports, 2001, 3: 149-155.
de Smet et al., [abstract] “Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon Angioplasty: A Study in the Atherosclerotic Yucatan Micropig.”Circulation, 2000, 101:2962-2967.
Farsak et al., “Detection ofChlamydia pneumoniaeandHelicobacter pyloriDNA in human atherosclerotic plaques by PCR.”J Clin Microbiol2000; 38(12):4408-11.
Fuchs et al., [abstract] “Anti-angiogenesis: A new potential strategy to inhibit restenosis”.Intl J Cardiovasc Intervent. 2001; 4:3-6.
Gallo et al., “Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle.”Circulation. 1999;99:2164-2170.
Grayston,Thomas J., “Antibiotic Treatment ofChlamydia pneumoniaefor secondary prevention of cardiovascular events.”Circulation. 1998;97:1669-1670.
Herdeg et al., [abstract] “Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.”J Am Coll CardiolJun. 2000; 35(7):1969-76.
Ismail et al., [abstract] “The role of infection in atherosclerosis and coronary artery disease: a new therapeutic target.”Heart Dis. 1999;1(4):233-40.
Kol et al., [abstract] “Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages.”J Clin Invest. 1999; 103:571-577.
Lowe et al., [abstract] “Coronary in-stent restenosis: Current status and future strategies.”J Am Coll Cardiol. Jan. 16, 2002; 39(2):183-93.
Lundemose et al., [abstract] “Chlamydia trachomatisMip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection.”Mol Microbial. 1993; 7(5):777-83.
Muhlestein et al., “Infection withChlamydia pneumoniaeaccelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model,”Circulation. 1998; 97:633-636.
Varenne, “Gene Therapy for Coronary Restenosis: A Promising Strategy for the New Millenium?”Current Interventional Cardiology Reports, 2000; 2: 309-315.
Barr Lynn
Seward Kirk Patrick
Wilber Judith Carol
Mercator Medsystems, Inc.
Sirmons Kevin C
Townsend and Townsend and Crew
Witczak Catherine N
LandOfFree
Methods and systems for delivering liquid substances to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and systems for delivering liquid substances to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and systems for delivering liquid substances to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032039